The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study

Summary

Patients with metabolic syndrome, insulin resistance, and elevated triglycerides of 150 mg/dl or higher will be randomized to one of four groups: 1) placebo; 2) metformin; 3) fenofibrate; or 4) combined metformin and fenofibrate for a period of 12 weeks after titration to target dose. We are interested in the effects of these therapies on triglyceride levels, HDL-C, insulin resistance, and markers of inflammation.

Timeline

Start

2005-08

Primary completion

2007-12

Completion

2008-03

Drugs

Indications